Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To investigate the effects of myeloma cells on the differentiation of osteoclast precursors (pOCs) into OCs in different culture systems in vitro and the interaction between OCs and myeloma cells.

Methods: Myeloma cell lines 8226, XG1 and XG7 and pOCs were cocultured in different culture system. OCs was examined by TRAP staining. RT-PCR was used to evaluate the expression of receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) of myeloma cells and the effects of myeloma cells on RANKL/OPG expression in coculture. The role of OCs in myeloma cells cycle was measured by FCM with PI staining. The supportive effects of OCs on myeloma cells survival were determined by FCM with double staining for annexin V and PI.

Results: 8226 and XG1 cells could directly stimulate the differentiation of pOCs into TRAP+ multinuclear mature OCs. Myeloma cells, which expressed neither RANKL nor OPG, upregulated RANKL expression and decreased OPG expression in mouse primary bone marrow stromal cells (pBMSC). When OCs were co-cultured with myeloma cells, all OCs apparently remained alive after 7 days while devoid of sRANKL and M-CSF. OCs stimulated the proliferation of myeloma cells in co-culture systems,the cell number increased to (3.8 +/- 0.1) x 10(5)/well, (3.9 +/- 0.1) x 10(5)/well, (4.0 +/- 0.1) x 10(5)/well, and to (8.7 +/- 0.1) x 10(5)/well, (9.1 +/- 0.1) x 10(5)/well, (9.0 +/- 0.1 ) x 10(5)/well after co-culture for 3 days and 7 days for XG1 cells, XG7 cells and 8226 cells, respectively (P <0.01). However, OCs could counteract cytotoxic effects of dexamethasone. The proportion of Annexin V-/PI- cells were 57.71%, 82.18% and 90.92% for 8226 cells, XG1 and XG7 cells after co-culture with OCs (P <0.01).

Conclusion: Myeloma cells stimulated the differentiation of pOCs into TRAP+ multinuclear mature OCs by directly and/or indirectly disrupting the balance of RANKL/OPG, OCs promoted MM cells growth and survival, thus maintaining a vicious circle between myeloma cells and osteoclasts.

Download full-text PDF

Source

Publication Analysis

Top Keywords

myeloma cells
32
+/- 105/well
24
105/well +/-
20
ocs myeloma
16
cells
13
myeloma
10
ocs
9
effects myeloma
8
8226 xg1
8
xg1 cells
8

Similar Publications

IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.

View Article and Find Full Text PDF

Background: Bone marrow (BM) Measurable Residual Disease (MRD) assessments underestimate disease burden in multiple myeloma, as focal lesions can exist outside the marrow. Functional imaging, like positron emission tomography-computed tomography (PET-CT), offers valuable insights into residual disease beyond the marrow. Combining marrow flow cytometry (FCM) with PET-CT for a composite MRD (cMRD) assessment before and after autologous stem cell transplant (ASCT) is expected to provide prognostic information, particularly in settings where patients receive extended duration of anti-myeloma therapy prior to ASCT.

View Article and Find Full Text PDF

A Rare Case of Plasmablastic Myeloma After Renal Transplant.

Exp Clin Transplant

August 2025

>From the University Clinic for Nephrology, Faculty of Medicine, Saints Cyril and Methodius University in Skopje, Skopje, North Macedonia.

Posttransplant lymphoproliferative disorders are a serious complication after solid-organ transplant, with a reported incidence from 2% to 20%. Plasma cell neoplasms in solid-organ transplants represent a rare but increasingly serious complication after solid-organ transplant. We report a case of plasmablastic myeloma, a very rare variant of multiple myeloma with aggressive course and poor prognosis.

View Article and Find Full Text PDF

Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.

View Article and Find Full Text PDF

Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.

View Article and Find Full Text PDF